Resmed
RMD
$202.37
-0.70%
ResMed Inc. is a global leader in the healthcare sector, specifically within the Medical - Instruments & Supplies industry, developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea and other respiratory conditions. The company is a dominant market player, distinguished by its integrated hardware and software ecosystem, which includes a growing focus on digital health platforms to provide clinical data for out-of-hospital care management. The current investor narrative is shaped by the company's structural growth drivers—such as increasing diagnosis rates for sleep apnea—juxtaposed against recent significant stock price weakness, which has sparked debate over whether this presents a long-term value opportunity or reflects deeper concerns about competitive pressures and market share dynamics in its core business.…
RMD
Resmed
$202.37
RMD 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Resmed's 12-month outlook, with a consensus price target around $263.08 and implied upside of +30.0% versus the current price.
Average Target
$263.08
14 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
14
covering this stock
Price Range
$162 - $263
Analyst target range
The stock is covered by 10 analysts, and while the specific Buy/Hold/Sell distribution and consensus recommendation are not explicitly provided in the data, recent institutional actions show a mix of 'Outperform', 'Equal Weight', and 'Hold' ratings, suggesting a neutral to cautiously optimistic sentiment. The average target price is not directly stated in the provided data; however, analyst estimates point to an average EPS forecast of $16.20 and average revenue of $7.78 billion for the upcoming period, which investors use to derive implied valuations. The target price range is also not specified, but the wide dispersion in recent analyst actions—including a downgrade from 'Outperform' to 'Neutral' by Baird in December—coupled with the stock's significant underperformance and high short ratio of 11.56, signals elevated uncertainty and a lack of strong conviction among the analyst community regarding near-term catalysts.
Bulls vs Bears: RMD Investment Factors
The investment debate for ResMed centers on a clash between deteriorating near-term momentum and strong underlying fundamentals. The bear case, currently supported by stronger evidence, is driven by severe price underperformance, decelerating revenue growth, and negative analyst sentiment. The bull case rests on the company's exceptional profitability, fortress balance sheet, and a forward valuation that appears to price in a recovery. The single most important tension is whether the recent revenue deceleration to 11% YoY is a temporary headwind or the beginning of a sustained slowdown in the core sleep apnea market. The resolution of this growth trajectory will determine if the current valuation compression is an overreaction or a justified reassessment of long-term prospects.
Bullish
- Strong Profitability & Margin Expansion: ResMed maintains exceptional profitability with a net margin of 27.6% and a gross margin that expanded sequentially from 61.46% to 62.18% in the last quarter. This demonstrates robust pricing power and effective cost control, even as revenue growth decelerates.
- Fortress Balance Sheet & Cash Generation: The company has a pristine balance sheet with a low debt-to-equity ratio of 0.14 and a high current ratio of 3.44. It generates substantial free cash flow ($1.79 billion TTM), providing ample internal resources for growth, buybacks, and dividends without financial stress.
- Attractive Forward Valuation: The stock's forward P/E of 16.9x is significantly lower than its trailing P/E of 27.0x, indicating the market is pricing in a meaningful earnings recovery. This forward multiple appears reasonable for a market leader with a PEG ratio of 0.72, suggesting growth is not fully priced in.
- Oversold Technical Condition: The stock is deeply oversold, trading near its 52-week low of $198.64 after a 20.6% decline over the last three months. This severe underperformance (-24.8% relative to the S&P 500 over 3 months) may have created a value opportunity if sentiment reverses.
Bearish
- Severe Revenue Growth Deceleration: Revenue growth has slowed markedly, with Q2 FY2026 YoY growth of 11.0% down from 14.3% in the prior quarter. This deceleration in the core business, which makes up 88% of sales, raises concerns about market saturation or competitive pressures.
- Sustained Negative Price Momentum: The stock is in a pronounced downtrend, with a 1-year decline of -13.3% and a 3-month plunge of -20.6%, severely underperforming the S&P 500. This negative momentum, coupled with a high short ratio of 11.56, reflects strong bearish sentiment and a lack of near-term catalysts.
- Premium Valuation Relative to Peers: Despite the sell-off, ResMed's trailing P/E of 27.0x still trades at a premium to its industry average. The stock's price-to-sales ratio of 7.36x is also elevated, leaving it vulnerable to further multiple compression if growth continues to slow.
- Analyst Uncertainty & Downgrades: Analyst sentiment is mixed with recent downgrades (e.g., Baird to Neutral) and a lack of strong conviction, as evidenced by the dispersion in ratings. This uncertainty, with 10 analysts providing coverage but no clear bullish consensus, suggests near-term visibility is poor.
RMD Technical Analysis
The stock is in a pronounced and sustained downtrend, with a 1-year price change of -13.31% and a more severe 6-month decline of -16.96%. As of the latest close at $205.02, the price is trading near the bottom of its 52-week range, at approximately 70% of the span between the 52-week low of $198.64 and high of $293.81, indicating the stock is in deeply oversold territory and may represent a value opportunity, though it carries the risk of being a 'falling knife' if the downtrend persists. Recent momentum is decisively negative and accelerating, with a 1-month decline of -8.00% and a 3-month plunge of -20.63%, significantly underperforming the S&P 500, which gained 9.98% and 4.14% over the same periods, respectively; this severe underperformance suggests strong negative sentiment and a lack of near-term catalysts. Key technical support is clearly defined at the 52-week low of $198.64, while resistance lies at the recent highs near the 52-week peak of $293.81; a breakdown below $198.64 would signal a continuation of the bearish trend, whereas a hold and reversal could indicate a bottoming process. With a beta of 0.928, the stock has exhibited slightly less volatility than the broader market during this turbulent period, which may offer some relative stability for risk-averse investors looking for entry points.
Beta
0.84
0.84x market volatility
Max Drawdown
-32.3%
Largest decline past year
52-Week Range
$199-$294
Price range past year
Annual Return
-18.3%
Cumulative gain past year
| Period | RMD Return | S&P 500 |
|---|---|---|
| 1m | -12.1% | +8.2% |
| 3m | -17.6% | +9.0% |
| 6m | -17.2% | +10.5% |
| 1y | -18.3% | +26.5% |
| ytd | -17.3% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RMD Fundamental Analysis
Revenue growth remains positive but has shown signs of deceleration; the most recent quarterly revenue (Q2 FY2026) was $1.42 billion, representing a year-over-year growth of 10.98%, yet this marks a slowdown from the 14.3% YoY growth seen in the prior quarter (Q1 FY2026 revenue of $1.34 billion), indicating potential headwinds in the core sleep and respiratory business which constitutes 88% of total sales. The company is highly profitable with robust margins; net income for the last quarter was $392.6 million, translating to a net margin of 27.6%, and the gross margin was a healthy 62.18%, which has expanded sequentially from 61.46% in the prior quarter, demonstrating strong pricing power and cost management despite revenue growth pressures. The balance sheet is exceptionally strong with low financial risk, evidenced by a low debt-to-equity ratio of 0.14 and a high current ratio of 3.44; the company generates substantial cash flow, with trailing twelve-month free cash flow of $1.79 billion, providing ample internal funding for growth initiatives, share buybacks, and dividends without reliance on external debt.
Quarterly Revenue
$1.4B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.62%
Latest Quarter
Free Cash Flow
$1.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RMD Overvalued?
Given the company's consistent profitability with a net income of $392.6 million, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio stands at 27.02x, while the forward PE is significantly lower at 16.90x, indicating the market expects a substantial rebound in earnings growth over the next twelve months. Compared to its industry, ResMed's trailing PE of 27.02x trades at a premium; while a direct industry average is not provided in the data, the forward multiple of 16.90x suggests the market is pricing in a normalization of earnings, though the premium likely reflects its market leadership and strong margins. Historically, the stock's current trailing PE of 27.02x is below its own recent historical range observed in the data, which has seen peaks above 30x in the past year (e.g., 28.76x in Q1 FY2026), suggesting the recent sell-off has compressed valuations and the stock is trading at a more reasonable level relative to its own history, though not at deeply distressed levels.
PE
27.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -90x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is revenue growth deceleration, which fell from 14.3% to 11.0% YoY between the last two quarters. While margins remain robust, this slowdown could pressure future earnings if it persists. The company's high revenue concentration in sleep/respiratory care (88% of sales) creates operational vulnerability to any single-market disruption. However, the exceptionally strong balance sheet (D/E of 0.14) and substantial cash generation ($1.79B FCF TTM) mitigate traditional financial risks, providing a buffer against downturns.
Market & Competitive Risks: The stock faces significant valuation compression risk, as its trailing P/E of 27.0x trades at a premium to industry peers despite the recent sell-off. Competitive pressures may be emerging, as suggested by the growth slowdown. The stock's beta of 0.928 indicates it is slightly less volatile than the market, but its severe underperformance (-42.3% relative to SPY over 1 year) suggests company-specific rather than macro headwinds. Sector rotation away from healthcare or medical devices could further pressure the multiple.
Worst-Case Scenario: The worst-case scenario involves a continuation of the current downtrend, where decelerating revenue growth confirms fears of market saturation or competitive share loss, leading to multiple compression and earnings downgrades. This could trigger a breakdown below the key technical support at the 52-week low of $198.64. A realistic downside could see the stock re-testing this level, representing a potential loss of approximately -3% from the current $205.02. A more severe bear case, aligning with the stock's maximum drawdown of -30.2%, could see a decline toward the $175-$180 range if sentiment completely collapses, representing a downside of -12% to -15%.